View in EDS HTML Full Text PDF Full Text

Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.

Saved in:
Bibliographic Details
Title: Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.
Authors: Torrado C; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Andersen CR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Kang L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Brink AL; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Adesoye T; Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Le H; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Patterson CJ; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Poullard A; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Osburn JA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Tan HN; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Gouda MA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Charles S; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Urschel GE; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Tang TY; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Hong DS; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Champiat S; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Naing A; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Dumbrava EE; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Piha-Paul SA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Rodon J; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.; Department of Experimental Therapeutics, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Pohlmann PR; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Fu S; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Source: The oncologist [Oncologist] 2026 Mar 09; Vol. 31 (4).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41830429
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Torrado+C%22">Torrado C</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Andersen+CR%22">Andersen CR</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Kang+L%22">Kang L</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Brink+AL%22">Brink AL</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Adesoye+T%22">Adesoye T</searchLink>; Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Le+H%22">Le H</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Patterson+CJ%22">Patterson CJ</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Poullard+A%22">Poullard A</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Osburn+JA%22">Osburn JA</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Tan+HN%22">Tan HN</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Gouda+MA%22">Gouda MA</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Charles+S%22">Charles S</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Urschel+GE%22">Urschel GE</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Tang+TY%22">Tang TY</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Champiat+S%22">Champiat S</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Dumbrava+EE%22">Dumbrava EE</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Rodon+J%22">Rodon J</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Yap+TA%22">Yap TA</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.; Department of Experimental Therapeutics, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Pohlmann+PR%22">Pohlmann PR</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2026 Mar 09; Vol. 31 (4).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41830429
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyag075
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Torrado C
      – PersonEntity:
          Name:
            NameFull: Andersen CR
      – PersonEntity:
          Name:
            NameFull: Kang L
      – PersonEntity:
          Name:
            NameFull: Brink AL
      – PersonEntity:
          Name:
            NameFull: Adesoye T
      – PersonEntity:
          Name:
            NameFull: Le H
      – PersonEntity:
          Name:
            NameFull: Patterson CJ
      – PersonEntity:
          Name:
            NameFull: Poullard A
      – PersonEntity:
          Name:
            NameFull: Osburn JA
      – PersonEntity:
          Name:
            NameFull: Tan HN
      – PersonEntity:
          Name:
            NameFull: Gouda MA
      – PersonEntity:
          Name:
            NameFull: Charles S
      – PersonEntity:
          Name:
            NameFull: Urschel GE
      – PersonEntity:
          Name:
            NameFull: Tang TY
      – PersonEntity:
          Name:
            NameFull: Hong DS
      – PersonEntity:
          Name:
            NameFull: Champiat S
      – PersonEntity:
          Name:
            NameFull: Naing A
      – PersonEntity:
          Name:
            NameFull: Tsimberidou AM
      – PersonEntity:
          Name:
            NameFull: Dumbrava EE
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Rodon J
      – PersonEntity:
          Name:
            NameFull: Yap TA
      – PersonEntity:
          Name:
            NameFull: Pohlmann PR
      – PersonEntity:
          Name:
            NameFull: Meric-Bernstam F
      – PersonEntity:
          Name:
            NameFull: Fu S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 03
              Text: 2026 Mar 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1